Literature DB >> 22691542

Extracellular human immunodeficiency virus type 1 viral protein R causes reductions in astrocytic ATP and glutathione levels compromising the antioxidant reservoir.

Adriano Ferrucci1, Michael R Nonnemacher, Eric A Cohen, Brian Wigdahl.   

Abstract

Patients infected with human immunodeficiency virus type 1 (HIV-1) often display neurological complications in late stage disease and increased viral loads directly correlated with higher concentrations of extracellular HIV-1 viral protein r (Vpr) in the blood serum and cerebrospinal fluid. Additionally, HIV-1-infected patients with a low CD4+ T-lymphocyte count displayed lower concentrations of reduced glutathione (GSH), the main intracellular antioxidant molecule, and lower level of survival. To establish a correlation between increased concentrations of extracellular Vpr and an oxidative stress-induced phenotype, the U-87 MG astroglioma cell line has been used to determine the downstream effects induced by Vpr. Conditioned media obtained from the human endothelial kidney (HEK) 293 T cell line transfected either in the absence or presence of HIV-1 Vpr contained free Vpr. Exposure of U-87 MG to this conditioned media decreased intracellular levels of both adenosine triphosphate (ATP) and GSH. These observations were recapitulated using purified recombinant HIV-1 Vpr both in U-87 MG and primary human fetal astrocytes in a dose- and time-dependent manner. Vpr-induced oxidative stress could be partly restored by co-treatment with the antioxidant molecule N-acetyl-cysteine (NAC). In addition, free Vpr augmented production of reactive oxygen species due to an increase in the level of oxidized glutathione (GSSG). This event was almost entirely suppressed by treatment with an anti-Vpr antibody or co-treatment with NAC. These studies confirm a role of extracellular Vpr in impairing astrocytic levels of intracellular ATP and GSH. Studies are underway to better understand the intricate correlation between reductions in ATP and GSH metabolites and how they affect neuronal survival in end-stage disease.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22691542      PMCID: PMC3398186          DOI: 10.1016/j.virusres.2012.06.002

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  52 in total

1.  Interaction between the HIV-1 protein Vpr and the adenine nucleotide translocator.

Authors:  Emmanuelle N Sabbah; S Druillennec; N Morellet; S Bouaziz; G Kroemer; B P Roques
Journal:  Chem Biol Drug Des       Date:  2006-02       Impact factor: 2.817

2.  HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration.

Authors:  Gareth J Jones; Nicola L Barsby; Eric A Cohen; Janet Holden; Kim Harris; Peter Dickie; Jack Jhamandas; Christopher Power
Journal:  J Neurosci       Date:  2007-04-04       Impact factor: 6.167

3.  Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction.

Authors:  Hiroko Kitayama; Yoshiharu Miura; Yoshinori Ando; Shigeki Hoshino; Yukihito Ishizaka; Yoshio Koyanagi
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

4.  Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases.

Authors:  Yong Xiao; Gang Chen; Jonathan Richard; Nicole Rougeau; Hongshan Li; Nabil G Seidah; Eric A Cohen
Journal:  Virology       Date:  2007-12-03       Impact factor: 3.616

5.  HIV-1 Vpr deregulates calcium secretion in neural cells.

Authors:  Inna Rom; Satish L Deshmane; Ruma Mukerjee; Kamel Khalili; Shohreh Amini; Bassel E Sawaya
Journal:  Brain Res       Date:  2009-03-25       Impact factor: 3.252

6.  Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression.

Authors:  Satish L Deshmane; Ruma Mukerjee; Shongshan Fan; Luis Del Valle; Carine Michiels; Thersa Sweet; Inna Rom; Kamel Khalili; Jay Rappaport; Shohreh Amini; Bassel E Sawaya
Journal:  J Biol Chem       Date:  2009-02-09       Impact factor: 5.157

7.  Autocrine glutamate signaling promotes glioma cell invasion.

Authors:  Susan A Lyons; W Joon Chung; Amy K Weaver; Toyin Ogunrinu; Harald Sontheimer
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

8.  Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia.

Authors:  Melissa J Churchill; Steven L Wesselingh; Daniel Cowley; Carlos A Pardo; Justin C McArthur; Bruce J Brew; Paul R Gorry
Journal:  Ann Neurol       Date:  2009-08       Impact factor: 10.422

9.  Vpr in plasma of HIV type 1-positive patients is correlated with the HIV type 1 RNA titers.

Authors:  Shigeki Hoshino; Binlian Sun; Mitsuru Konishi; Mari Shimura; Tatsuya Segawa; Yoshiaki Hagiwara; Yoshio Koyanagi; Aikichi Iwamoto; Jun-Ichi Mimaya; Hiroshi Terunuma; Shigeyuki Kano; Yukihito Ishizaka
Journal:  AIDS Res Hum Retroviruses       Date:  2007-03       Impact factor: 2.205

10.  Human immunodeficiency virus type 1 efficiently binds to human fetal astrocytes and induces neuroinflammatory responses independent of infection.

Authors:  Jinliang Li; Galina Bentsman; Mary Jane Potash; David J Volsky
Journal:  BMC Neurosci       Date:  2007-05-12       Impact factor: 3.288

View more
  18 in total

Review 1.  Defining the roles for Vpr in HIV-1-associated neuropathogenesis.

Authors:  Tony James; Michael R Nonnemacher; Brian Wigdahl; Fred C Krebs
Journal:  J Neurovirol       Date:  2016-04-07       Impact factor: 2.643

2.  Specific amino acids in HIV-1 Vpr are significantly associated with differences in patient neurocognitive status.

Authors:  Will Dampier; Gregory C Antell; Benjamas Aiamkitsumrit; Michael R Nonnemacher; Jeffrey M Jacobson; Vanessa Pirrone; Wen Zhong; Katherine Kercher; Shendra Passic; Jean W Williams; Tony James; Kathryn N Devlin; Tania Giovannetti; David J Libon; Zsofia Szep; Garth D Ehrlich; Brian Wigdahl; Fred C Krebs
Journal:  J Neurovirol       Date:  2016-07-11       Impact factor: 2.643

3.  HIV-1 Vpr disrupts mitochondria axonal transport and accelerates neuronal aging.

Authors:  Ying Wang; Maryline Santerre; Italo Tempera; Kayla Martin; Ruma Mukerjee; Bassel E Sawaya
Journal:  Neuropharmacology       Date:  2017-02-14       Impact factor: 5.250

4.  HIV-1 Vpr increases Env expression by preventing Env from endoplasmic reticulum-associated protein degradation (ERAD).

Authors:  Xianfeng Zhang; Tao Zhou; Dylan A Frabutt; Yong-Hui Zheng
Journal:  Virology       Date:  2016-06-23       Impact factor: 3.616

5.  Extracellular HIV-1 viral protein R affects astrocytic glyceraldehyde 3-phosphate dehydrogenase activity and neuronal survival.

Authors:  Adriano Ferrucci; Michael R Nonnemacher; Brian Wigdahl
Journal:  J Neurovirol       Date:  2013-06-01       Impact factor: 2.643

Review 6.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

7.  Intracellular expression of Tat alters mitochondrial functions in T cells: a potential mechanism to understand mitochondrial damage during HIV-1 replication.

Authors:  Sara Rodríguez-Mora; Elena Mateos; María Moran; Miguel Ángel Martín; Juan Antonio López; Enrique Calvo; María Carmen Terrón; Daniel Luque; Delphine Muriaux; José Alcamí; Mayte Coiras; María Rosa López-Huertas
Journal:  Retrovirology       Date:  2015-09-16       Impact factor: 4.602

Review 8.  Heme oxygenase-1 dysregulation in the brain: implications for HIV-associated neurocognitive disorders.

Authors:  Surendra S Ambegaokar; Dennis L Kolson
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

Review 9.  Role of Oxidative Stress in HIV-1-Associated Neurocognitive Disorder and Protection by Gene Delivery of Antioxidant Enzymes.

Authors:  Jean-Pierre Louboutin; David Strayer
Journal:  Antioxidants (Basel)       Date:  2014-11-18

Review 10.  Oxidative Stress during HIV Infection: Mechanisms and Consequences.

Authors:  Alexander V Ivanov; Vladimir T Valuev-Elliston; Olga N Ivanova; Sergey N Kochetkov; Elizaveta S Starodubova; Birke Bartosch; Maria G Isaguliants
Journal:  Oxid Med Cell Longev       Date:  2016-10-13       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.